IBISWorld Platform
Answer any industry question in minutes with our entire database at your fingertips.
Oncosil Medical Limited
Oncosil Medical is a Public Company that generates the majority of its income from the Medical and Surgical Equipment Manufacturing industry. In 2025 the company generated total revenue of $1,171,000 including sales and other revenue. The exact number of employees for this organisation is not available. The Chief Executive of Oncosil Medical is Mr Nigel Lange whose official title is Chief Executive Officer & Managing Director. The Chairman of Oncosil Medical is Mr Thomas Duthy whose official title is Non-Executive Chairman. Oncosil Medical Limited is an ASX listed medical device company focused on Interventional Oncology. The company provides the following product to healthcare professionals: The OncoSil™ device – This device is a single-use internal radiation device used to deliver a pre-determined dose of beta radiation directly into cancerous tissue. It is currently approved in the European Union, the United Kingdom, Hong Kong, Singapore, Malaysia, New Zealand, Switzerland, Turkey, and Israel.
Access this data your way
The Oncosil Medical Limited Industry analysis is available in multiple formats to fit seamlessly into your workflow.
API Data Delivery
Feed trusted, human-driven industry intelligence straight into your platform.
Integrations
Streamline your workflow with IBISWorld’s intelligence built into your toolkit.
What's included in this industry analysis
IBISWorld's research coverage on the Oncosil Medical Limited includes market sizing, forecasting, data and analysis. The most recent publication will be as current as of March 2026.
Company Details
What’s this enterprise profile about?
Oncosil Medical Limited, trading as Oncosil Medical, operates under the ABN 89 113 824 141 and was incorporated on 14 April 2005. Oncosil Medical Limited trades on the Australian Securities Exchange under the ticker code ASX:OSL. Oncosil Medical Limited primarily operates in the General Practice Medical Services industry in Australia.
Key Personnel
What’s included in the Key Personnel chapter?
The Key Personnel chapter outlines the principal leadership positions within Oncosil Medical Limited, including the Chairman, Board members, Chief Executive Officer, and other key management personnel. It provides an overview of the company’s governance and executive structure, along with a breakdown of gender diversity across leadership roles, offering insight into the composition of the organisation’s senior team.
Financials
What’s included in the Financials chapter?
The Financials chapter presents Oncosil Medical Limited’s historical financial performance, including detailed profit and loss statements outlining sales revenue, cost of sales, and profitability. It also incorporates balance sheet data, providing a breakdown of assets and liabilities, as well as additional financial metrics such as the number of shares on issue. Together, these disclosures offer a comprehensive view of the company’s financial position and performance over time.
Growth & Ratios
What’s included in the Growth & Rations chapter?
The Growth & Ratios chapter provides historical data on key financial performance indicators, enabling an assessment of the company’s operational efficiency, profitability, and financial structure over time. Metrics covered include return on equity, return on assets, profit margins, revenue per employee, as well as gearing and leverage ratios, offering a comprehensive view of performance trends and capital management.
Operating Segments
What’s included in the Operating Segments chapter?
The Operating Segments chapter provides an overview of the revenue composition and asset allocation across the various industries in which Oncosil Medical Limited operates. It offers insights into how the company’s financial performance is distributed among its core business segments, highlighting the relative contribution of each industry to total revenue.
Competitor Benchmarking
What’s included in the Competitor Benchmarking chapter?
The Competitor Benchmarking chapter includes a comparative assessment of Oncosil Medical Limited’s key financial, growth, and valuation ratios against industry averages to evaluate its competitive position. It analyses valuation metrics such as price-to-earnings, price-to-book, enterprise value to EBITDA, and enterprise value to sales, alongside core financial indicators including liquidity ratios and profitability measures.
Shareholders
What’s included in the Shareholders chapter?
The Shareholders chapter provides a breakdown of the ownership structure of Oncosil Medical Limited, identifying key shareholders and outlining their respective ownership interests. This section offers insight into the concentration of shareholdings, the presence of institutional or strategic investors, and the overall distribution of equity within the company.
Subsidiaries
What’s included in the Subsidiaries chapter?
The Subsidiaries chapter provides an overview of the companies and business entities that are wholly or partially owned by Oncosil Medical Limited. It outlines the ownership structure of each subsidiary, offering insight into the broader corporate group and how these entities contribute to the company’s overall activities and performance.
History
What’s included in the History chapter?
The History chapter presents a overview of Oncosil Medical Limited’s development, highlighting key milestones and significant corporate events since its incorporation. It includes the company’s incorporation date and outlines major strategic, operational, and structural developments, providing context for its evolution and current market position.
Trusted by industry professionals
More than 6,000 businesses use IBISWorld to shape local and global economies
We were able to supplement our reports with IBISWorld’s information from both a qualitative and quantitative standpoint. All of our reporting now features some level of IBISWorld integration.
IBISWorld delivers the crisp business knowledge we need to drive our business. Whether it be serving up our major clients, winning new business or educating on industry issues, IBISWorld brings real value.
IBISWorld has revolutionised business information — which has proved commercially invaluable to exporters, investors and public policy professionals in Australia and overseas.
When you’re able to speak to clients and be knowledgeable about what they do and the state that they operate in, they’re going to trust you a lot more.
Frequently Asked Questions
What is Oncosil Medical Limited?
Oncosil Medical Limited is an ASX listed medical device company focused on Interventional Oncology. The company provides the following product to healthcare professionals: The OncoSil™ device – This device is a single-use internal radiation device used to deliver a pre-determined dose of beta radiation directly into cancerous tissue. It is currently approved in the European Union, the United Kingdom, Hong Kong, Singapore, Malaysia, New Zealand, Switzerland, Turkey, and Israel.
What industry does Oncosil Medical Limited operate in?
Oncosil Medical Limited, trading as Oncosil Medical, is a Public Company that generates the majority of its income from the General Practice Medical Services industry in Australia.
Where is Oncosil Medical Limited located?
Murray Cod Australia Limited company is based at 7 Eden Park Drive, Macquarie, New South Wales, Australia.
Who is the CEO of Oncosil Medical Limited?
The Chief Executive Officer & Managing Director of Oncosil Medical Limited is Thomas Duthy and the Chief Executive Officer & Managing Director is Nigel Lange.
What was Oncosil Medical Limited’s revenue in 2025?
In 2025, Oncosil Medical Limited generated total revenue of approximately $1.2 million.
Cut through the noise with intelligence you can trust
